Dana Davis

Title: Dana Davis - Innovator in Protease Inhibition and Angiogenesis

Introduction

Dana Davis is a prominent inventor based in Santa Clara, CA (US). She has made significant contributions to the field of biochemistry, particularly in the development of novel compounds that target specific biological processes. With a total of 2 patents, her work has the potential to impact various therapeutic areas.

Latest Patents

One of Dana's latest patents is titled "Cyanoalkylamino derivatives as protease inhibitors." This invention focuses on novel cyanoalkylamino derivatives that act as inhibitors of cysteine proteases, including cathepsins K, S, B, and L, with a particular emphasis on cathepsin K. The patent outlines pharmaceutical compositions comprising these compounds, methods for treating diseases associated with unregulated cysteine protease activity, and techniques for preparing these compounds. Another significant patent is for "VEGF peptides and their use for inhibiting angiogenesis." This patent describes a peptide that includes the amino acid sequence QKRKRKKSRYKSWSVP, which is part of the vascular endothelial growth factor (VEGF) and has demonstrated the ability to inhibit angiogenesis.

Career Highlights

Throughout her career, Dana has worked with notable companies such as Ark Therapeutics Limited and Merck Frosst Canada & Co. Her experience in these organizations has contributed to her expertise in the development of innovative therapeutic solutions.

Collaborations

Dana has collaborated with esteemed colleagues, including David Lawrence Selwood and Ian Zachary. These partnerships have fostered a collaborative environment that enhances the research and development of her inventions.

Conclusion

Dana Davis is a trailblazer in the field of biochemistry, with her innovative patents paving the way for advancements in medical treatments. Her work exemplifies the impact of dedicated research and collaboration in the pursuit of scientific progress.